Akribion Therapeutics (“Akribion”), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life. The study, published in Nature Communications, ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

This complex microbial dance seems to have a really important role in our health. Oral diseases and even oral cancers have ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.

SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on novel cancer treatments, announced today the appointment of Dan Kirby (NYSE:KEX) as Chief ...